Back to top
more

USANA Health Sciences (USNA)

(Real Time Quote from BATS)

$45.10 USD

45.10
32,045

+1.78 (4.11%)

Updated Jul 11, 2024 02:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (152 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for USNA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

USANA Health Sciences, Inc. [USNA]

Reports for Purchase

Showing records 101 - 120 ( 127 total )

Company: USANA Health Sciences, Inc.

Industry: Medical - Drugs

Record: 101

04/19/2013

Daily Note

Pages: 22

Q1 Consumer Sector Preview: Inclement Winter Weather Along with Currency Impacts to Challenge Q1 Results, Particularly for Callaway Golf

Provider: WEDBUSH SECURITIES INC.

Analyst: DIONISIO R

Price: 75.00

Research Provided by a Third Party

Company: USANA Health Sciences, Inc.

Industry: Medical - Drugs

Record: 102

02/06/2013

Company Report

Pages: 10

Upgrading to NEUTRAL Due to Stronger-Than-Expected Asia Plus Recent MLM Selloff

Provider: WEDBUSH SECURITIES INC.

Analyst: DIONISIO R

Price: 25.00

Research Provided by a Third Party

Company: USANA Health Sciences, Inc.

Industry: Medical - Drugs

Record: 103

01/21/2013

Daily Note

Pages: 22

Q4 Consumer Sector Preview

Provider: WEDBUSH SECURITIES INC.

Analyst: DIONISIO R

Price: 75.00

Research Provided by a Third Party

Company: USANA Health Sciences, Inc.

Industry: Medical - Drugs

Record: 104

10/24/2012

Company Report

Pages: 9

Q3 Upside on Asia Pickup and Effect of Sales Promotion; Maintain UNDERPERFORM, but Raising PT to $40

Provider: WEDBUSH SECURITIES INC.

Analyst: DIONISIO R

Price: 25.00

Research Provided by a Third Party

Company: USANA Health Sciences, Inc.

Industry: Medical - Drugs

Record: 105

08/17/2012

Company Report

Pages: 9

Short-Term Promotion Aimed at Helping Productivity and Distributor Retention; Maintain UNDERPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: DIONISIO R

Price: 25.00

Research Provided by a Third Party

Company: USANA Health Sciences, Inc.

Industry: Medical - Drugs

Record: 106

07/25/2012

Company Report

Pages: 9

Q1 Upside Surprise on Sales Promotion, Lower Tax Rate; Maintain UNDERPERFORM, but Raising PT to $37

Provider: WEDBUSH SECURITIES INC.

Analyst: DIONISIO R

Price: 25.00

Research Provided by a Third Party

Company: USANA Health Sciences, Inc.

Industry: Medical - Drugs

Record: 107

07/12/2012

Daily Note

Pages: 21

Q2 Consumer Sector Preview

Provider: WEDBUSH SECURITIES INC.

Analyst: DIONISIO R

Price: 75.00

Research Provided by a Third Party

Company: USANA Health Sciences, Inc.

Industry: Medical - Drugs

Record: 108

04/25/2012

Company Report

Pages: 9

Pre-Buying Before Asia Price Increases Drives Q1 Upside; Maintain UNDERPERFORM, but Raising PT to $34

Provider: WEDBUSH SECURITIES INC.

Analyst: DIONISIO R

Price: 25.00

Research Provided by a Third Party

Company: USANA Health Sciences, Inc.

Industry: Medical - Drugs

Record: 109

02/08/2012

Company Report

Pages: 9

Inline Q4 Results, but 2012 EPS Guidance Below Consensus; Lower EstImates, Maintain UNDERPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: DIONISIO R

Price: 25.00

Research Provided by a Third Party

Company: USANA Health Sciences, Inc.

Industry: Medical - Drugs

Record: 110

01/19/2012

Daily Note

Pages: 23

Q4:11 Consumer Products Earnings Preview

Provider: WEDBUSH SECURITIES INC.

Analyst: DIONISIO R

Price: 75.00

Research Provided by a Third Party

Company: USANA Health Sciences, Inc.

Industry: Medical - Drugs

Record: 111

10/26/2011

Company Report

Pages: 9

Solid Q3 Results, but Concerns over N. America Recruiting Trends Remain; Maintain UNDERPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: DIONISIO R

Price: 25.00

Research Provided by a Third Party

Company: USANA Health Sciences, Inc.

Industry: Medical - Drugs

Record: 112

10/13/2011

Daily Note

Pages: 24

Q3:11 Consumer Products Earnings Preview

Provider: WEDBUSH SECURITIES INC.

Analyst: DIONISIO R

Price: 75.00

Research Provided by a Third Party

Company: USANA Health Sciences, Inc.

Industry: Medical - Drugs

Record: 113

07/27/2011

Company Report

Pages: 9

Q2 Results Relatively In Line; Accelerating North American Active Associate Decline Troublesome

Provider: WEDBUSH SECURITIES INC.

Analyst: DIONISIO R

Price: 25.00

Research Provided by a Third Party

Company: USANA Health Sciences, Inc.

Industry: Medical - Drugs

Record: 114

07/06/2011

Company Report

Pages: 8

Potential Threat of Distributor Attrition to Competitive Start-Up, Led by Former Executives

Provider: WEDBUSH SECURITIES INC.

Analyst: DIONISIO R

Price: 25.00

Research Provided by a Third Party

Company: USANA Health Sciences, Inc.

Industry: Medical - Drugs

Record: 115

06/29/2011

Company Report

Pages: 8

Preannounces Q2 Results Ahead of Expectations on Change to China Integration Strategy

Provider: WEDBUSH SECURITIES INC.

Analyst: DIONISIO R

Price: 25.00

Research Provided by a Third Party

Company: USANA Health Sciences, Inc.

Industry: Medical - Drugs

Record: 116

04/27/2011

Company Report

Pages: 9

Solid Asia and Benefit from F/X, Partially Offset by Sluggish US Recruiting Trends

Provider: WEDBUSH SECURITIES INC.

Analyst: DIONISIO R

Price: 25.00

Research Provided by a Third Party

Company: USANA Health Sciences, Inc.

Industry: Medical - Drugs

Record: 117

02/09/2011

Company Report

Pages: 10

Q4 Earnings Miss and Tepid 2011 Guidance

Provider: WEDBUSH SECURITIES INC.

Analyst: DIONISIO R

Price: 25.00

Research Provided by a Third Party

Company: USANA Health Sciences, Inc.

Industry: Medical - Drugs

Record: 118

01/06/2011

Daily Note

Pages: 11

Q4:10 Earnings Preview

Provider: WEDBUSH SECURITIES INC.

Analyst: DIONISIO R

Price: 25.00

Research Provided by a Third Party

Company: USANA Health Sciences, Inc.

Industry: Medical - Drugs

Record: 119

10/28/2010

Company Report

Pages: 9

Raising PT and Estimates on Solid Q3 Upside, but U.S. Still Sluggish and Upcoming China Challenges Loom

Provider: WEDBUSH SECURITIES INC.

Analyst: DIONISIO R

Price: 25.00

Research Provided by a Third Party

Company: USANA Health Sciences, Inc.

Industry: Medical - Drugs

Record: 120

10/15/2010

Daily Note

Pages: 10

Consumer Products: Q3:10 Earnings Preview

Provider: WEDBUSH SECURITIES INC.

Analyst: DIONISIO R

Price: 25.00

Research Provided by a Third Party